Welcome to our dedicated page for Thermo Fishr Sci news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fishr Sci stock.
Thermo Fisher Scientific Inc. (NYSE: TMO) is frequently in the news as the world leader in serving science, with disclosures and press releases covering its activities across life sciences, diagnostics, analytical instruments and pharma services. News about Thermo Fisher often highlights how the company’s technologies and services support customers in accelerating life sciences research, solving analytical challenges, improving laboratory productivity, enhancing diagnostics and enabling the development and manufacture of life‑changing therapies.
Recent Thermo Fisher news includes strategic collaborations, regional investments, product clearances, capital allocation decisions and financing transactions. The company announced a collaboration with NVIDIA to power AI‑based solutions and laboratory automation, pairing its scientific instruments and lab software with NVIDIA’s AI infrastructure to increase automation, accuracy and speed in laboratories. It also reported an expansion of its bioprocessing capabilities in Asia through Bioprocess Design Centers in Incheon, Hyderabad and Singapore, aimed at supporting the region’s biopharmaceutical industry.
Thermo Fisher’s news flow also covers regulatory and clinical milestones, such as 510(k) clearance in the United States for the EXENT System, an automated platform designed as an aid in the diagnosis of multiple myeloma and related disorders. Financial and corporate updates include announcements of euro‑denominated and U.S. dollar‑denominated senior note offerings, a $5 billion share repurchase authorization, quarterly dividends, and agreements and completions related to acquisitions such as Solventum Corporation’s purification and filtration business and Clario Holdings, Inc.
Visitors to this TMO news page can review a stream of these company‑specific developments, from earnings‑related announcements and conference presentations to leadership changes and strategic initiatives disclosed in press releases and SEC‑linked communications.
Thermo Fisher Scientific (NYSE: TMO) will release Q1 2026 financial results before the market opens on Thursday, April 23, 2026 and will host a conference call the same day at 8:30 a.m. ET.
The call will be webcast via the company website Investors section, with U.S. dial-in (833) 470-1428, international +1 (646) 844-6383 and access code 723173. A replay will be available through July 22, 2026.
Thermo Fisher Scientific (NYSE:TMO) completed the acquisition of Clario Holdings for $8.875 billion in cash, with an additional $125 million payable January 2027 and up to $400 million in performance-based earn-outs. The business joins Thermo Fisher's Laboratory Products and Biopharma Services segment and is expected to grow in the high single digits, be accretive to adjusted operating margin, and contribute $0.45 of adjusted EPS in the first year. Management expects approximately $175M of adjusted operating income from synergies by year five.
Clario’s platform has supported roughly 70% of FDA and EMA novel drug approvals over the past decade, enhancing Thermo Fisher’s clinical research data capabilities.
Thermo Fisher Scientific (NYSE: TMO) said its Board authorized a quarterly cash dividend of $0.47 per common share, payable April 15, 2026 to shareholders of record as of March 13, 2026. This represents a 10% increase from the prior quarterly dividend of $0.43.
Thermo Fisher Scientific (NYSE: TMO) said Marc N. Casper, chairman, president and CEO, will present at the Raymond James Institutional Investors Conference on March 3, 2026 at 9:15 a.m. ET. A live webcast will be available in the company's Investors section, with a replay accessible shortly after the presentation.
Thermo Fisher (NYSE: TMO) priced a $3.8 billion offering of USD-denominated senior notes across four maturities: $1.0B 4.215% due 2031, $750M 4.550% due 2033, $1.3B 4.902% due 2036, and $750M 5.546% due 2046.
The offering is expected to close on or about February 12, 2026, with semi-annual interest. Net proceeds are intended to pay part of the cash consideration for the pending Clario acquisition or for general corporate purposes pending closing.
Thermo Fisher Scientific (NYSE: TMO) reported Q4 2025 revenue of $12.21B (up 7%) and full-year 2025 revenue of $44.56B (up 4%).
GAAP diluted EPS was $5.21 for Q4 and $17.74 for the year; adjusted EPS was $6.57 Q4 and $22.87 for 2025. The company deployed $16.5B of capital in 2025, including $13B for M&A and returned $3.6B to shareholders.
Thermo Fisher Scientific (NYSE: TMO) announced a strategic collaboration with NVIDIA on January 12, 2026 to integrate NVIDIA AI infrastructure into Thermo Fisher instruments and lab software.
The partnership will use NVIDIA DGX Spark, NVIDIA NeMo and NVIDIA BioNeMo to add AI-driven automation, improve accuracy and speed workflows, connect instruments and data to AI models, and advance autonomous or “lab-in-the-loop” scientific workflows that aim to reduce manual steps and accelerate research.
Henry Schein (Nasdaq: HSIC) appointed Frederick M. Lowery as Chief Executive Officer, effective March 2, 2026. Mr. Lowery will join the Board of Directors and succeeds Stanley M. Bergman, who will step down as CEO after 35 years and remain Chairman to support a leadership transition. Mr. Lowery brings more than two decades of healthcare distribution and operations experience, most recently serving as Executive Vice President and President, Laboratory Products and BioProduction at Thermo Fisher (NYSE: TMO). The appointment is presented as alignment with Henry Schein’s BOLD+1 strategic plan and aims to accelerate growth and value creation.
Thermo Fisher Scientific (NYSE:TMO) announced that Marc N. Casper, chairman, president and CEO, will present at the J.P. Morgan 2026 Healthcare Conference on Tuesday, January 13, 2026 at 11:15 a.m. ET.
A live webcast will be available in the company's Investors section at www.thermofisher.com, with a replay accessible shortly after the presentation concludes.
Thermo Fisher Scientific (NYSE: TMO) will release its fourth-quarter and full-year 2025 financial results before the market opens on Thursday, January 29, 2026. The company will hold a conference call the same day at 8:30 a.m. ET to discuss financial performance and future expectations.
The call will be webcast live in the Investors section of www.thermofisher.com. U.S. dial-in is (833) 470-1428; international dial-in is +1 (646) 844-6383; access code 054943. The earnings release and related materials will appear under Financials, and a replay will be available under News, Events & Presentations through Wednesday, April 22, 2026.